Alterola Biotech, Inc. Announces Executive Changes
October 05, 2021 at 05:09 pm EDT
Share
Alterola Biotech, Inc. announced that on September 28, 2021, the board of directors and shareholders removed Larson Elsmore as Vice Chairman, Secretary and Director. On the same date, the board of directors appointed Seamus McAuley as the company’s Secretary. Also on September 28, 2021, the board of directors resolved to terminate all existing advisory boards of the company and to establish an Audit and Compliance Committee, with Ning Qu to serve as Chairperson. Also on September 28, 2021, the board of directors appointed Hunter Land to serve as Director and Vice President of Translational Research.
Alterola Biotech, Inc. is a pharmaceutical company. The Company is engaged in the development of cannabinoid, cannabinoid-like, and non-cannabinoid pharmaceutical active pharmaceutical ingredients (APIs); pharmaceutical medicines made from cannabinoid, cannabinoid-like, and non-cannabinoid APIs; and European food approval of cannabinoid-based, cannabinoid-like, and non-cannabinoid ingredients and products. The Company has three areas of focus: development of regulated pharmaceuticals (human and animal health) and regulated food products; production of APIs and food-grade ingredients; and formulation, and drug delivery, providing bioavailability, solubility, and stability. It also focuses on developing new medicines from various sources, including botanical, traditional chemical synthesis, and biosynthetic methodologies. Its wholly owned subsidiaries include ABTI Pharma Ltd, Phytotherapeutix Ltd, and Ferven Ltd.
ALTEROLA BIOTECH, INC. 
